Letter to the Editors

# Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab

Rasmus Ehren[1], Sandra Habbig[1]

[1] University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Pediatrics, Cologne, Germany

Corresponding author

Dr. Rasmus Ehren

Pediatric Nephrology, Children's and Adolescents' Hospital, Cologne, Germany

Kerpener Str. 62, 50937 Köln, Germany

Phone: +49 (0)221 – 478 42101

Fax: +49 (0)221 – 478 5835

Email: rasmus.ehren@uk-koeln.de

Supplementary table 1

| patient | sex | age at onset of disease (years) | age at investigation (years) | etiology of aHUS | genetic findings | factor H auto-antibodies | duration of eculizumab therapy before switch to ravulizumab (months) | complications during ravulizumab therapy | additional therapy |
|---|---|---|---|---|---|---|---|---|---|
| **1** | female | 7 | 8 | DEAP-HUS | CFHR1/2del, homozygous | positive | 6 | none | mycophenolate mofetil |
| **2** | male | 0.7 | 18 | CFH mutation | c.2770T>A, homozygous | negative | 123 | none | none |
| **3** | male | 0.5 | 10 | CFH mutation | c.2827_2831delGCTCA, heterozygous | negative | 103 | none | none |
| **4** | female | 0.4 | 9 | CFH mutation | c.3565C>T, heterozygous | negative | 74 | none | none |
| **5** | male | 15 | 20 | C3 mutation | c.481C>T, heterozygous | negative | 53 | none | none |
| **6** | female | 0.4 | 6 | CFH mutation | c.3644G>A, heterozygous | negative | 65 | none | none |

**Supplementary table 1:** Characteristics of the six patients with genetically and clinically proven atypical hemolytic uremic syndrome. (aHUS, atypical hemolytic uremic syndrome; C3, complement factor 3; CFH, complement factor H; CFHR1/2, complement factor H-related proteins 1/2; DEAP-HUS, deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome; del, deletion)